Advaxis Inc. plans to sell its common stock in an underwritten public offering.
The company plans to grant the underwriters an option to buy up to an additional 15% of the shares offered.
Advaxis plans to use the net proceeds to fund its continued research and development initiatives in connection with expanding the product pipeline and for other general corporate purposes.
Jefferies and Guggenheim Securities are acting as joint book-running managers for the offering.
